A Tumor-Targeted Replicating Oncolytic Adenovirus Ad-TD-nsIL12 as a Promising Therapeutic Agent for Human Esophageal Squamous Cell Carcinoma.
Zifang Zhang, Chunyang Zhang, Jinxin Miao...
https://pubmed.ncbi.nlm.nih.gov/33182528/Actively Recruiting
Led by Capital Medical University · Updated on 2024-02-28
18
Participants Needed
1
Research Sites
156 weeks
Total Duration
Researchers are evaluating the safety, tolerability, and toxicity of a new oncolytic virus called Ad-TD-nsIL12, given by injection into tumors, for children aged 1 to 18 years with newly diagnosed diffuse intrinsic pontine glioma DIPG. This early phase 1 clinical trial uses a dose escalation design to observe how patients respond to the virus treatment according to standard safety criteria NCI-CTCAE V5.0. Participants will receive multiple intratumoral injections of Ad-TD-nsIL12 after undergoing a stereotactic biopsy and placement of an Ommaya reservoir through the biopsy channel. Two injections are given shortly after surgery, spaced 3 days apart, followed by additional injections every 3 weeks plus or minus 4 days. The virus doses vary based on patient cohorts, ranging from 3x109 to 3x1010 viral particles suspended in 1 ml saline. During the trial, patients will be monitored closely with safety assessments at 3 months after the virus injection. Researchers will also evaluate tumor response at 3 months, overall survival at 12 months, and quality of life over 2 years. Sample collections will occur at 3 months to support these evaluations. This study is led by Capital Medical University and runs until 2028, focusing on careful observation of patients throughout the course of treatment and follow-up.
CONDITIONS
Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma
X
Xiao Qian, Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Capital Medical University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Initial injections with a 3-day interval followed by subsequent injections every 3 weeks ±4 days
Participants receive multiple intratumoral injections of the oncolytic virus Ad-TD-nsIL12 through an Ommaya reservoir inserted after stereotactic biopsy.
2 injections within first week and additional injections every 3 weeks
Duration - Up to 2 years after virus injection
Participants are monitored for safety, tumor response, overall survival, quality of life, and sample collection after completing treatment.
Visits at 3 months, 12 months, and 2 years post-injection
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Zifang Zhang, Chunyang Zhang, Jinxin Miao...
https://pubmed.ncbi.nlm.nih.gov/33182528/Pengju Wang, Xiaozhu Li, Jiwei Wang...
https://pubmed.ncbi.nlm.nih.gov/29123084/Sergia Bortolanza, Maria Bunuales, Itziar Otano...
https://pubmed.ncbi.nlm.nih.gov/19223865/Capital Medical University
Lead Sponsor